These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Inflammation in diabetes mellitus: role of peroxisome proliferator-activated receptor-alpha and peroxisome proliferator-activated receptor-gamma agonists. Libby P; Plutzky J Am J Cardiol; 2007 Feb; 99(4A):27B-40B. PubMed ID: 17307056 [TBL] [Abstract][Full Text] [Related]
26. Oxidized LDL regulates vascular endothelial growth factor expression in human macrophages and endothelial cells through activation of peroxisome proliferator-activated receptor-gamma. Inoue M; Itoh H; Tanaka T; Chun TH; Doi K; Fukunaga Y; Sawada N; Yamshita J; Masatsugu K; Saito T; Sakaguchi S; Sone M; Yamahara Ki ; Yurugi T; Nakao K Arterioscler Thromb Vasc Biol; 2001 Apr; 21(4):560-6. PubMed ID: 11304473 [TBL] [Abstract][Full Text] [Related]
27. PPARγ-independent thiazolidinedione-mediated inhibition of NUR77 expression in vascular endothelial cells. Hu Y; Liu HB; Simpson RW; Dear AE J Endocrinol; 2011 Jan; 208(1):R1-7. PubMed ID: 20978184 [TBL] [Abstract][Full Text] [Related]
28. Peroxisome proliferator-activated receptor gamma (PPARgamma) activation and its consequences in humans. Bar-Tana J Toxicol Lett; 2001 Mar; 120(1-3):9-19. PubMed ID: 11323157 [TBL] [Abstract][Full Text] [Related]
29. A dominant-negative peroxisome proliferator-activated receptor gamma (PPARgamma) mutant is a constitutive repressor and inhibits PPARgamma-mediated adipogenesis. Gurnell M; Wentworth JM; Agostini M; Adams M; Collingwood TN; Provenzano C; Browne PO; Rajanayagam O; Burris TP; Schwabe JW; Lazar MA; Chatterjee VK J Biol Chem; 2000 Feb; 275(8):5754-9. PubMed ID: 10681562 [TBL] [Abstract][Full Text] [Related]
30. Potential for peroxisome proliferator-activated receptor-gamma agonists in progression: beyond metabolism. Fogo AB Curr Opin Nephrol Hypertens; 2008 May; 17(3):282-5. PubMed ID: 18408479 [TBL] [Abstract][Full Text] [Related]
31. Angiotensin type 1 receptor antagonists induce human in-vitro adipogenesis through peroxisome proliferator-activated receptor-gamma activation. Janke J; Schupp M; Engeli S; Gorzelniak K; Boschmann M; Sauma L; Nystrom FH; Jordan J; Luft FC; Sharma AM J Hypertens; 2006 Sep; 24(9):1809-16. PubMed ID: 16915030 [TBL] [Abstract][Full Text] [Related]
32. Peroxisome proliferator-activated receptor-γ activation with angiotensin II type 1 receptor blockade is pivotal for the prevention of blood-brain barrier impairment and cognitive decline in type 2 diabetic mice. Min LJ; Mogi M; Shudou M; Jing F; Tsukuda K; Ohshima K; Iwanami J; Horiuchi M Hypertension; 2012 May; 59(5):1079-88. PubMed ID: 22454480 [TBL] [Abstract][Full Text] [Related]
33. Diabetes and cardiovascular risk markers. Erdmann E Curr Med Res Opin; 2005; 21 Suppl 1():S21-8. PubMed ID: 15811196 [TBL] [Abstract][Full Text] [Related]
34. Telmisartan is a promising cardiometabolic sartan due to its unique PPAR-gamma-inducing property. Yamagishi S; Takeuchi M Med Hypotheses; 2005; 64(3):476-8. PubMed ID: 15617852 [TBL] [Abstract][Full Text] [Related]
35. Expression of peroxisome proliferator-activated receptor gamma (PPARgamma) in rat aortic smooth muscle cells. Iijima K; Yoshizumi M; Ako J; Eto M; Kim S; Hashimoto M; Sugimoto N; Liang YQ; Sudoh N; Toba K; Ouchi Y Biochem Biophys Res Commun; 1998 Jun; 247(2):353-6. PubMed ID: 9642130 [TBL] [Abstract][Full Text] [Related]
36. Telmisartan but not valsartan inhibits TGF-beta-mediated accumulation of extracellular matrix via activation of PPARgamma. Yao Y; Zou R; Liu X; Jiang J; Huang Q; He Y; Li M; Wang S; Zhou J; Ma D; Xu G J Huazhong Univ Sci Technolog Med Sci; 2008 Oct; 28(5):543-8. PubMed ID: 18846335 [TBL] [Abstract][Full Text] [Related]